Patients lost an average of 20.2% of their weight with tirzepatide over 72 weeks versus 13.7% with semaglutide.

Venous thromboembolism is a risk with several contemporary HRT formulations, consistent with earlier data. Several ...

December 4, 2024 | Béla Merkely and C. Michael Gibson discuss the results of a CRT-D upgrade versus ICD alone for HFrEF patients with right ventricular pacing. Receive the the latest news, research, ...